FLT3 and acute myeloid leukemia: The distinct molecular and pharmacological features of gilteritinib, quizartinib, and crenolanib have shaped their clinical trajectories, with each agent pursuing complementary therapeutic niches in relapsed/refractory disease, upfront combinations, post-transplant maintenance, and even FLT3–wild-type AML [49].